Trial Profile
A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with docetaxel to placebo in combination with docetaxel in first line metastatic Castrate Resistant Prostate Cancer (mCRPC)
Status:
Suspended
Phase of Trial:
Phase II/III
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs Masitinib (Primary) ; Docetaxel; Prednisone
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors AB Science
- 26 Jun 2023 Results presented in an AB Science media release.
- 26 Jun 2023 According to an AB Science media release, announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating (mCRPC) with its lead compound masitinib, based on findings from this phase 3 study of AB12003. This new European patent provides intellectual property protection for masitinib in the treatment of mCRPC until 2042.
- 04 Dec 2021 This trial has been completed in Greece, according to European Clinical Trials Database record.